PDCD1 and diffuse large B-cell lymphoma: Therefore, we hypothesize that regulating the strong local immunosuppression of DLBCL by counteracting PD-1 and its ligands could not only improve the outcomes of EBV+DLBCL immunotherapy, but also improve the efficacy of conventional DLBCL therapy.